The authors noticed that content of “Conflicts of Interest” in the original version [1] was missing and would like to make a correction:
It should be changed from “Conflicts of Interest: The authors declare no conflict of interest.” to “Conflicts of Interest: Nadia Hindi reports grants, personal fees and non-financial support from PharmaMar, personal fees from Eli Lilly, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, Bristol Myers Squibb, Pfizer and Daichii-Sankyo. Irene Carrasco García, Alberto Sánchez-Camacho, Johanna Benedetti, Pilar Sancho, and Paloma Santos declare research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, and Daichii–Sankyo. Paloma Sanchez-Bustos and David S. Moura report institutional research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer, and Pfizer. Javier Martin-Broto reports research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly, and Company, Bayer, and Eisai; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly, and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GlaxoSmithKline, Novartis, Blueprint, Nektar, Forma, Amgen, Bristol Myers Squibb, Pfizer, and Daichii-Sankyo. All the other authors report no conflicts of interest.”
We apologize for this error and state that the scientific conclusions are unaffected. The original article has been updated.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reference
- 1.Hindi N., Carrasco García I., Sánchez-Camacho A., Gutierrez A., Peinado J., Rincón I., Benedetti J., Sancho P., Santos P., Sánchez-Bustos P., et al. Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center. Cancers. 2020;12:3740. doi: 10.3390/cancers12123740. [DOI] [PMC free article] [PubMed] [Google Scholar]